Statins down under [1]

British Journal of Clinical Pharmacology

Volumn 63, Issue 1, 2007, Pages 125-127

  Mant, Andrea ^a   Lowinger, Jocelyn ^a   Hall, Wayne ^b   Whicker, Susan ^c   Ringland, Clare ^a   Stark, Helen ^a  

^a UNIVERSITY OF NEW SOUTH WALES   (Australia)

^b UNIVERSITY OF QUEENSLAND   (Australia)

^c NONE

Author keywords

[No Author keywords available]

Indexed keywords

ATORVASTATIN; CERIVASTATIN; FLUINDOSTATIN; HYDROXYMETHYLGLUTARYL COENZYME A REDUCTASE INHIBITOR; PRAVASTATIN; SIMVASTATIN;

AUSTRALIA; CLINICAL TRIAL; DRUG DISTRIBUTION; DRUG FORMULATION; DRUG USE; DRUG UTILIZATION; HEALTH BEHAVIOR; HEALTH CARE; HEART INFARCTION; HUMAN; ISCHEMIC HEART DISEASE; LETTER; MEDICAL PRACTICE; MORTALITY; PATIENT COMPLIANCE; PRESCRIPTION; PRIORITY JOURNAL; TREATMENT OUTCOME;

AUSTRALIA; DRUG UTILIZATION REVIEW; HUMANS; HYDROXYMETHYLGLUTARYL-COA REDUCTASE INHIBITORS;

EID: 33845427349     PISSN: 03065251     EISSN: 13652125     Source Type: Journal    
DOI: 10.1111/j.1365-2125.2006.02735.x     Document Type: Letter

References (8)

1. Walley T, Folio-Gallo P, Stephens P, Van Gause E. Trends in the utilization of statins and other lipid-lowering drugs across Europe 1997-2003. Br J Clin Pharmacol 2005; 60: 543-551.
2. OECD Health Data 2005: Statistics and Indicators for 30 Countries, accessed at http://www.oecd.org.
3. WHO Collaborating Centre for Drug Statistics Methodology. Guidelines for ATC Classification and DDD Assignment, 9th edn. WHO, Oslo, 2005: p. 22.
4. Unal B, Critchley JA, Capewell S. Modelling the decline in coronary heart disease deaths in England and Wales, 1981-2000: comparing contributions from primary prevention and secondary prevention. BMJ 2005: bmj.38561 633345 8F.
5. Magrini N, Einarson T, Vaccheri A, McManus P, Montanaro N, Bergman U. Use of lipid-lowering drugs from 1990 to 1994: an international comparison among Australia, Finland, Italy (Emilia Romagna Region), Norway and Sweden. Eur J Clin Pharmacol 1997; 53: 185-9.
6. Pedersen TR, Faergeman O, Kastelein JJ, Olsson AG, Tikkanen MJ, Holme I, Larse ML, Bendiksen FS, Lindahl C, Szarek M, Tsai J. High-dose atorvastatin vs. usual-dose simvastatin for secondary prevention after myocardial infarction: the IDEAL study: a randomized controlled trial. JAMA 2005, 294: 2437-45.
7. Stocks N, Ryan P, McElroy H, Allan J. Statin prescribing in Australia: socioeconomic and sex differences. A cross-sectional study. Med J Aust 2004; 180: 229-31.
8. National Heart Foundation of Australia and the Cardiac Society of Australia and New Zealand. Position Statement on Lipid Management. Heart Lung Circulation 2005; 14: 275-91.